casimersen
Selected indexed studies
- Casimersen. (, 2012) [PMID:36580568]
- Casimersen: First Approval. (Drugs, 2021) [PMID:33861387]
- Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. (Muscle Nerve, 2021) [PMID:34105177]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Casimersen. (2012) pubmed
- Casimersen: First Approval. (2021) pubmed
- Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. (2021) pubmed
- Casimersen. (2021) pubmed
- Casimersen (AMONDYS 45™): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy. (2024) pubmed
- Casimersen for Duchenne muscular dystrophy. (2021) pubmed
- AMONDYS 45 (Casimersen), a Novel Antisense Phosphorodiamidate Morpholino Oligomer: Clinical Considerations for Treatment in Duchenne Muscular Dystrophy. (2023) pubmed
- Casimersen for the treatment of Duchenne muscular dystrophy. (2022) pubmed
- Casimersen (Amondys 45) for Duchenne muscular dystrophy. (2021) pubmed
- Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. (2022) pubmed